Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers. The allosteric inhibitor SHP099 stabilizes the wild-type SHP2 enzyme in an autoinhibited conformation that is...

Descripción completa

Detalles Bibliográficos
Autores principales: LaRochelle, Jonathan R., Fodor, Michelle, Vemulapalli, Vidyasiri, Mohseni, Morvarid, Wang, Ping, Stams, Travis, LaMarche, Matthew J., Chopra, Rajiv, Acker, Michael G., Blacklow, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207684/
https://www.ncbi.nlm.nih.gov/pubmed/30375388
http://dx.doi.org/10.1038/s41467-018-06823-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207684/
https://www.ncbi.nlm.nih.gov/pubmed/30375388
http://dx.doi.org/10.1038/s41467-018-06823-9

Ejemplares similares